GLP-1 agonists will have a disease modifying effect on OA because less load to bear will reduce the rate of degeneration of the joint (I’d expect). And that’s great.
What it won’t do is reverse the process, and turn degeneration into regeneration, as we now have evidence for from 008.
I don’t see GLP-1 agonists as a major concern. They’re competitive in the same way as, say, physiotherapy or diet.
General OA media and info, page-436
-
- There are more pages in this discussion • 235 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
0.035(12.7%) |
Mkt cap ! $108.4M | |||
| Open | High | Low | Value | Volume |
| 27.5¢ | 31.0¢ | 27.5¢ | $108.9K | 371.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 17420 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |